<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03181087</url>
  </required_header>
  <id_info>
    <org_study_id>MCHHFoshan-1701</org_study_id>
    <nct_id>NCT03181087</nct_id>
  </id_info>
  <brief_title>Safety of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars</brief_title>
  <official_title>A Phase I, Single-arm, Open Study of the Safety of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maternal and Child Health Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maternal and Child Health Hospital of Foshan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of umbilical cord mesenchymal stem cell
      local intramuscular injection for treatment of uterine scars by a prospective, single-center,
      open, and single-arm clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 11, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation through vital signs, the results of clinical lab tests and adverse events</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Safety evaluation through vital signs, the results of clinical lab tests and adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with uterine niche</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>The niche is defined as a triangular anechoic area at the presumed site of incision in the uterus by transvaginal utrasonography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of uterine scar thickness</measure>
    <time_frame>6 weeks, 3 and 6 months post treatment</time_frame>
    <description>The scar thickness be measured using a transvaginal utrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of uterine scar area</measure>
    <time_frame>6 weeks, 3 and 6 months post treatment</time_frame>
    <description>The scar area will be measured using a transvaginal utrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with endometritis</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Endometritis is defined as the presence of at least two of the following signs with no other recognized cause: fever (temperature of at least 38℃), abdominal pain, uterine tenderness, or purulent drainage from the uterus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with wound infection</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Wound infection is defined as the presence of either superficial or deep incisional surgical-site infection characterized by cellulitis or erythema and induration around the incision or purulent discharge from the incision site with or without fever and included necrotizing fasciitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin concentrations in breast milk and serum</measure>
    <time_frame>6 weeks, 3 and 6 months post treatment</time_frame>
    <description>Breast milk and serum immunoglobulin (IgG, IgA, IgM) and the complement (C3, C4) are detected by transmission immune turbidity method using automatic biochemical analyzer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events occurrence</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Adverse events will be evaluated since the baseline visit until 6 months after the end of the treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Uterine Scar</condition>
  <arm_group>
    <arm_group_label>Umbilical cord MSCs Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1*10^7 Umbilical cord Mesenchymal Stem Cells (MSCs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Umbilical cord MSCs</intervention_name>
    <description>Participants will receive direct local intramuscular injection of 1*10^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.</description>
    <arm_group_label>Umbilical cord MSCs Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primiparous women receiving cesarean delivery

          -  Ages between 21-35 years

          -  Gestation ages ≥ 37 weeks and &lt; 42 weeks

          -  Willing to comply with study dosing and completed the entire course of the study

          -  Willing to give and sign an informed consent form and a photographic release form

        Exclusion Criteria:

          -  Fibroids

          -  Placenta previa

          -  Placenta abruption

          -  Multiple gestation

          -  Antepartum hemorrhage

          -  Preeclampsia/Eclampsia

          -  Hepatic or renal dysfunction

          -  Any systemic uncontrolled disease

          -  Inability to provide consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhengping Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maternal and Child Health Hospital of Foshan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhengping Liu, MD</last_name>
    <phone>+ 86 757 82969772</phone>
    <email>liuzphlk81@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dazhi Fan, MD</last_name>
    <phone>+ 86 757 82969772</phone>
    <email>fdz1988@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maternal and Child Health Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deqin Jia, BD</last_name>
      <phone>+ 86 757 82969772</phone>
      <email>trials_fs_mchh@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Dazhi Fan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2017</study_first_submitted>
  <study_first_submitted_qc>June 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maternal and Child Health Hospital of Foshan</investigator_affiliation>
    <investigator_full_name>Zhengping Liu, MD</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Cesarean Section</keyword>
  <keyword>Uterine Scar</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

